XML 105 R26.htm IDEA: XBRL DOCUMENT v2.4.0.6
Segment Information (Notes)
 12 Months Ended
Dec. 31, 2011
Segment Reporting [Abstract]  
Segment Information
Segment Information

In 2011, the Company continued its heightened operational focus to improve the Company’s customer service and focus on driving consistent organic growth. This focus consisted of management team changes, redefining the organizational structure, insourcing of certain administrative functions, improving employee relations, reallocating resources to align employee interests, reinforcing a commitment to compliance, and an overall organization-wide focus on the customer. As part of this process, the Company's new management team reorganized the business into two operating segments. These segments are based on the operations of the underlying businesses and the customers they serve and will make it easier for the Company to further unify its sales, marketing and service offerings for the given businesses. Based on the "management approach", as defined by the authoritative guidance for disclosures about segments and enterprise related information, the Company's two reporting segments are LTC and SCG. The Company's larger reportable segment is LTC, which primarily provides distribution of pharmaceuticals, related pharmacy consulting and other ancillary services and medical supplies. LTC's customers are primarily skilled nursing, assisted living and other providers of healthcare services in 47 states in the United States, the District of Columbia and in Canada at December 31, 2011.  The Company’s other reportable segment is SCG which provides key commercialization services for the biopharmaceutical industry in addition to end-of-life pharmaceutical care management for hospice care agencies. The primary components of the "Corporate/Other" segment are the Company's corporate management oversight and administration, including its information technology and data management services, as well as other consolidating and eliminating entries, which have not been charged to reportable segments. The Company evaluates the performance of its segments based on revenue and operating income, and does not include segment assets or nonoperating income/expense items for management reporting purposes. All prior period segment information has been recast to reflect Omnicare's new segment reporting.

The table below presents information about the segments as of and for the years ended December 31, 2011, 2010 and 2009 (in thousands):

 
 
For the years ended December 31,
2011:
 
LTC
 
SCG
 
Corporate/Other
 
Consolidated
Totals
Net sales
 
$
5,123,477

 
$
1,044,191

 
$
15,254

 
$
6,182,922

Depreciation and amortization expense
 
(64,484
)
 
(16,221
)
 
(52,427
)
 
(133,132
)
Settlement, litigation and other related charges
 
(55,031
)
 
(643
)
 
—

 
(55,674
)
Other miscellaneous charges, net
 
(15,049
)
 
—

 
(1,044
)
 
(16,093
)
Operating income (loss) from continuing operations
 
476,800

 
98,938

 
(142,795
)
 
432,943

2010:
 
 

 
 

 
 

 
 

Net sales
 
$
5,175,730

 
$
838,790

 
$
16,150

 
$
6,030,670

Depreciation and amortization expense
 
(58,271
)
 
(17,094
)
 
(75,181
)
 
(150,546
)
Settlement, litigation and other related charges
 
(113,279
)
 
(430
)
 
—

 
(113,709
)
Other miscellaneous charges, net
 
(13,745
)
 
(14,173
)
 
(119,313
)
 
(147,231
)
Operating income (loss) from continuing operations
 
374,110

 
75,039

 
(259,995
)
 
189,154

2009:
 
 

 
 

 
 

 
 

Net sales
 
$
5,271,388

 
$
712,768

 
$
16,897

 
$
6,001,053

Depreciation and amortization expense
 
(71,389
)
 
(18,461
)
 
(47,832
)
 
(137,682
)
Settlement, litigation and other related charges
 
(77,449
)
 
—

 
—

 
(77,449
)
Other miscellaneous charges, net
 
(16,281
)
 
(163
)
 
(9,263
)
 
(25,707
)
Operating income (loss) from continuing operations
 
530,600

 
87,972

 
(148,821
)
 
469,751


The Company's operations are primarily in the United States with one pharmacy located in Canada which is not material to the consolidated sales or total assets of Omnicare.